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ABSTRACT
Purpose In order to identify challenges in pediatric pharmacoepidemiological safety studies, we assessed the characteristics of such
(published) studies.
Methods Relevant articles from inception to 2013 were retrieved from Embase and Medline. We sequentially screened titles, abstracts and
full texts with independent validation. We systematically collected data regarding general information, study methods and results.
Results Out of 4825 unique articles, 268 full texts (5.6%) were retained; 147 (54.9%) pertained to drugs rather than vaccines. Considering
the 268 studies, 202 (75.4%) concerned children and adolescents (2 to 11 years) and 14 (5.3%) included preterm newborns. Most studies
originated from North America (154 [57.5%]) or Europe (92 [34.3%]). Only 47 studies (17.5%) were privately funded. The majority
(174 [64.9%]) were cohort studies. Out of 268 studies, 196 (73.1%) collected data retrospectively; paper medical charts were the most com-
mon data source for the exposures (85 [31.7%]) and outcomes (122 [45.5%]). Only 3 (2.0%) drug-only studies investigated rarely used
drugs. Considering all 268 studies, only 27 (10.1%) reported sample size or power calculation. Most (75 [51.0%]) drug-only studies
corrected confounding by multivariate modeling unlike stratiﬁcation in 66 (55.9%) vaccine-only studies. Considering 75 child-only studies
without any statistically signiﬁcant result, 41 (54.7%) did not discuss lack of power.
Conclusions Although the ﬁeld of pediatric pharmacoepidemiology is steadily developing evaluation seldom includes neonates, is mainly
focused on few drug classes and safety outcomes and concerns mainly drug use in developed countries. Small study size is a speciﬁc
challenge in pediatrics. Reporting should be improved. © 2016 The Authors. Pharmacoepidemiology and Drug Safety Published by John
Wiley & Sons Ltd.
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INTRODUCTION
Legislation has been introduced to stimulate the con-
duct of clinical trials in children,1–3 leading to more
evidence on efﬁcacy of new drugs or new formulations
of existing drugs in children.4 This laudable action has
greatly improved the evidence for new drugs but does
not impact much on the available safety data because
information on rare and potentially more serious safety
issues cannot be obtained from randomized clinical tri-
als (RCTs).5–6
Safety data can be generated more efﬁciently from
postmarketing observational studies,7–8 particularly
relevant in children among whom the use of drugs is
high and frequently off-label but recorded in routine
care records.9 The availability of large scale healthcare
and claims databases provides an outstanding oppor-
tunity to perform safety studies. However, because
the studies are observational, their design requires extra
attention to avoid misclassiﬁcation and address
potential confounding. Although the ﬁeld of
pharmacoepidemiology has grown substantially in the
last 20years, very few researchers focus on pediatrics.
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As part of the Global Research in Paediatrics—
Network of Excellence (http://www.grip-network.org/),
we conducted a systematic review of the medical
literature in order to assess the characteristics of
pharmacoepidemiological studies evaluating the safety
of drugs in children.
METHODS
Search strategy
We conducted this review according to PRISMA
guidelines.10 We identiﬁed relevant articles by system-
atically searching EMBASE.COM and MEDLINE
(via OvidSP) from inception to 29 November 2013.
We used the following abbreviated search strategy:
“children” AND “pharmacoepidemiology” AND
“comparative studies”. Details of the full search strat-
egy are included in Appendix 1. The computer-based
searches were conducted by a biomedical information
specialist (WB), and were limited to human research
without language limitations. One reviewer (OO) man-
ually searched the bibliographies of relevant articles
for additional relevant studies.
Study selection
All observational studies with the main objective to
quantify the association between a drug exposure(s)
and the occurrence of adverse drug reaction(s) in chil-
dren and adolescents (≤18years of age) were eligible
for inclusion in the review. Studies that included both
children and adults were also retained. Drug exposures
concerned all medicinal products including vaccines,
applied either systemically or locally, and adverse
drug reactions (ADRs) concerned all clinical events
described as adverse outcomes to an individual (or
combination of) drug(s) and/or vaccine(s).
We excluded RCTs and observational studies that
evaluated drug safety signal detection in spontaneous
reporting systems, compliance rates to medicinal treat-
ments, incidence or prevalence of ADRs or other dis-
eases within a deﬁned population, teratogenic effects
of drug exposure in pregnancy or through breast milk,
medication errors, accidental and intentional poison-
ing, drug abuse, management of ADRs or other
diseases, pharmacogenomics, pharmacoeconomics,
health services utilization, environmental exposures
or herbal treatments. We excluded case series, case
reports, abstracts, letters, duplicate studies, prelimi-
nary publications or reviews. Only studies published
in English were retained for the analysis.
All titles and abstracts were initially screened by
one reviewer (OO) and full texts of potentially
relevant articles were retrieved. A second reviewer
(FK), blinded to the initial assessment, independently
screened a sample of abstracts that comprised all ab-
stracts retained plus a random selection of abstracts
rejected by the ﬁrst reviewer. Any disagreements be-
tween the two reviewers were examined by a third
reviewer (G’tJ). Full texts retained through this pro-
cess were independently screened by two reviewers
(OO and JD), disagreements were examined by a
third reviewer (CF).
Data collection
We developed a standardized form that was tested on
10 randomly selected papers, and was modiﬁed
accordingly.
Data collected from each study pertained to journal
impact factor (measured in 2013), study design, study
period, type of data, study population, exposure, out-
come, statistical analysis and results. We used country
of corresponding author as a proxy for study setting. In
the absence of information regarding study design, de-
signs were classiﬁed based on data reviewers’ judg-
ment. Case control studies included those studies that
applied the nested case control design. Type of data
implied primary versus secondary data (i.e. ‘large’
datasets like ‘primary care (prescription) data’, ‘outpa-
tient (pharmacy) dispensing data’ and ‘claims data’).
The age of the study population was categorized
according to guidelines deﬁned by the International
Conference on Harmonization (ICH)11: newborns (0–
27days), infants and toddlers (28days–23months),
children (2–11years) and adolescents (12–18years).
We used the term drug to refer to small molecules as
opposed to vaccines. Exposures and outcomes were
classiﬁed as rare based on authors’ deﬁnitions. For
the sources of exposure data, inpatient dispensing data
included electronic prescription data for hospitalized
patients, medical charts at the clinic implied paper
charts, outpatient dispensing data implied pharmacy
dispensing records, and registry included those that re-
corded information on vaccination and drug use. To
assess whether follow-up was long enough to observe
the outcomes of interest in cohort studies, we applied
the following minimum time intervals from drug expo-
sure: fever—1day, other acute events—2weeks,
cancer and other chronic (i.e. neurological and psychi-
atric) events—5years. The full data extraction form is
given in Appendix 2.
Both drugs and vaccines were mapped to the World
Health Organization-Anatomical Therapeutic Chemi-
cal (WHO-ATC) classiﬁcation (second or ﬁfth level
codes). The outcomes were mapped to the main
o. u. osokogu et al.862
© 2016 The Authors. Pharmacoepidemiology and Drug Safety
published by John Wiley & Sons Ltd.
Pharmacoepidemiology and Drug Safety, 2016; 25: 861–870
divisions of the International Classiﬁcation of Dis-
eases (ICD), ninth edition.
Two reviewers (OO and JD) independently col-
lected data from all full text articles. Discrepancies
were discussed with three senior reviewers (FK, DW
and CF).
In order to check for the impact of the Best Pharma-
ceuticals for Children Act (BPCA) which was intro-
duced in the US in 2002,3 we compared the number
of pediatric studies published before and after its intro-
duction. We compared pediatric studies to all the
published studies (i.e. pertaining to the general
population).
Data analysis
All continuous variables were described using medians
(ﬁrst [Q1]–third [Q3] quartiles) and categorical vari-
ables were summarized using counts and percentages.
We performed hypothesis testing using the Mann–
Whitney U test for continuous variables and Pearson
chi-square, Fischer’s exact test or Z test for categorical
variables. Analysis was performed by utilizing Statisti-
cal Package for the Social Sciences (SPSS) version 21.
RESULTS
The search strategy yielded 4825 unique records after
de-duplication (Figure 1). After screening titles and
abstracts, we retained 301 articles (inter-reviewer con-
cordance 90%) and after full text review, we retained
268 for analysis (inter-reviewer concordance 92%).
General characteristics of the studies
The 268 retained studies were published from 1979 to
2013. In Figure 2, we compare the 268 studies to the
total number (30,098) of studies (pertaining to the
Figure 1. Flow chart depicting the selection of relevant papers
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general population) published during the same period.
After 2002, the number of pediatric studies steadily
increased, more studies (196 [73.1%]) were published
during the 10-year period from 2003 to 2013, com-
pared to studies (72 [26.9%]) published during the pre-
ceding 24-year period.
Most studies originated from North America (154
[57.5%]) or Europe (92 [34.3%]) and most studies
(147 [54.9%]) assessed only drugs. Only three stud-
ies (1.1%) evaluated both drugs and vaccines, the
studies investigated only children for the effect of
the following drug classes (WHO-ATC second
level): ‘corticosteroids for systemic use’, ‘ántibacte-
rials for systemic use’, ‘cough and cold prepara-
tions’ and ‘anti-inﬂammatory and anti-rheumatic
products’. The investigated vaccines were
‘diphtheria–tetanus–pertussis’, ‘measles–mumps–
rubella’, ‘hepatitis B virus’, ‘óral polio virus’ and
‘inactivated polio virus’.
Considering 268 studies, 183 (68.3%) included only
children, the remainder studied both children and
adults. Studies on drug safety evaluation included
most frequently children aged 2–11years while vac-
cine safety studies were most frequently conducted in
infants and toddlers (Table 1). Only 14 studies
(5.0%) included preterm newborns.
The median impact factor of the journals in which
the studies were published was 3.8 (3.1–5.3). As seen
in Table 1, vaccine-only studies (4.6 [3.6–5.6]) were
published in higher impact journals than drug-only
studies (3.7 [2.6–5.5]) (Mann–Whitney U p-value
0.01). Few studies were published in pediatric (88
[32.8%]) or pharmacoepidemiological specialty (30
[11.2%]) journals. Only 14 studies (17.5%) were
privately funded, vaccine studies were more frequently
publicly funded but for a large proportion the type of
funding was unknown. Regardless of the type of expo-
sure that was investigated, privately funded studies
(journal impact factor=3.5; 3.1–5.3) were of lower
impact than studies receiving public funding (journal
impact factor=5; 3.5–7.8) (Mann–Whitney U p-
value<0.01).
Methodology of the studies
From the 268 studies, 202 (75.4%) reported the study
design(s) and for the remaining study design was clas-
siﬁed according to the reviewers’ judgment. Cohort
studies were the most common (174 [64.9%]), and
23 studies (8.6%) applied more than one design.
Case-only designs were seldom used: the self-
controlled case series (SCCS) design was utilized in
only 30 studies (11.2%), to evaluate vaccine-related
outcomes exclusively. Similarly, case-crossover stud-
ies were few (4 [1.5%]).
In most studies (196 [73.1%]), data collection
was retrospective. Prospective studies (88 [32.8%])
were usually cohort studies that used mainly pri-
mary data (56 [63.6%]) and were smaller than stud-
ies with retrospective data. Secondary data was
utilized for both drugs and vaccines and concerned
183 studies (68.3%). Studies using secondary data
had larger sample sizes than studies using primary
data collection. Exposure and outcome data were
collected from mainly medical charts ((85
[31.7%]) and (122 [45.5%]) respectively) followed
by claims data and primary care medical or dispens-
ing data (Table 2).
Out of 147 studies that evaluated drugs exclusively,
87 (59.2%) assessed only exposures to speciﬁc com-
pounds (i.e. amoxicillin), 51 (34.7%) evaluated expo-
sures to a speciﬁc drug class (i.e. ‘antibacterials for
systemic use’), only 9 (6.1%) assessed both speciﬁc
compound and drug class. Regarding the 96 studies
that assessed speciﬁc compounds, 54 (56.3%) investi-
gated only one compound, 20 (20.8%) assessed two
compounds and 22 (22.9%) assessed three or more.
Given the 60 studies that assessed drug class, 45
(75.0%) investigated only one class, 7 (11.7%)
Figure 2. Number of pharmacoepidemiological safety studies in children.
Note: In order to retrieve all published pharmacoepidemiological safety
studies that investigated the general population, we applied the same search
algorithm that was utilized for studies in children except that for the former,
we did not limit to the pediatric population; papers that were published in
2013 are those papers that were indexed in Embase and Medline as at 29
November
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Table 1. General characteristics for 268 pharmacoepidemiological studies that evaluated the safety of drugs and vaccines in children (≤18 years)
Total (268)
Type of exposure investigated
Only drugs (147) Only vaccines (118)
Number(%) or
median(Q1–Q3)
Number(%) or
median(Q1–Q3)
Number(%) or
median(Q1–Q3) p-Value
Continent of the corresponding author 0.90
North America 154 (57.5) 83 (56.5) 70 (59.3)
Europe 92 (34.3) 52 (35.4) 39 (33.1)
Asia 12 (4.5) 7 (4.8) 4 (3.4)
Others 10 (3.7) 5 (3.4) 5 (4.2)
Type of journal 0.07
Pediatric specialty 88 (32.8) 45 (30.6) 42 (35.6)
Pharmacology/pharmacoepidemiology 30 (11.2) 21 (14.3) 7 (5.9)
General medical* 39 (14.6) 17 (11.6) 22 (18.6)
Others† 111 (41.4) 64 (43.5) 47 (39.8)
2013 two-year journal impact factor 3.8 (3.1–5.3) 3.7 (2.6–5.5) 4.6 (3.6–5.6) 0.01
Missing data 18 (6.7) 14 (9.5) 4 (3.4)
Funding sources <0.01
Public 96 (35.8) 38 (25.9) 55 (46.6)
Private 47 (17.5) 25 (17.0) 22 (18.6)
Public and private 26 (9.7) 14 (9.5) 12 (10.2)
No funding 7 (2.6) 5 (3.4) 2 (1.7)
Funding not reported 92 (34.3) 65 (44.2) 27 (22.9)
Study period, years 3.7 (1.7–8.9) 4.6 (1.7–9.0) 3.2 (1.7–7.0) 0.31
Missing data 14 (5.2) 11 (4.1) 3 (1.1)
Study population‡
Age at inclusion
Minimum age, years 0.1 (0–2.0) 0.1 (0–3.0) 0.2 (0–1.0) 0.51
Maximum age, years 16.5 (2.0–21.0) 18.0 (13.5–63.5) 5.0 (1.5–17.0) <0.01
Preterm newborns <0.01
Exclusively 9 (3.3) 9 (6.1) 0
Partially 5 (1.9) 4 (2.7) 1 (0.8)
No 254 (94.8) 134 (91.2) 117 (99.2)
Term newborns (0–27 days) 106 (39.5) 61 (41.5) 44 (37.3) 0.49
Infants/toddlers (28 days–23months) 168 (62.9) 80 (54.4) 86 (72.9) <0.01
Children (2–11 years) 202 (75.4) 117 (80.0) 82 (69.5) 0.05
Adolescents (12–18 years) 157 (58.9) 110 (74.8) 45 (38.1) <0.01
Mixed (adults and children) 85 (31.7) 67 (45.6) 18 (15.3) <0.01
WHO-ATC level of investigated
exposure (reported name)§
<0.01
Fifth level (speciﬁc compound) 203 (75.7) 87 (59.2) 116 (98.3)
Second,third or fourth level (class) 51 (19.0) 51 (34.7) 0
Both 14 (5.2) 9 (6.1) 2 (1.7)
Number of speciﬁc compounds (WHO-
ATC ﬁfth level) that were investigated¶
0.14
1 137 (63.1) 54 (56.3) 81 (68.6)
2 35 (16.1) 20 (20.8) 15 (12.7)
≥3 45 (20.7) 22 (22.9) 22 (18.6)
Number of drug/vaccine classes (WHO-
ATC second, third or fourth level) that
were investigated∥
0.27
1 48 (73.8) 45 (75.0) 1 (50.0)
2 8 (12.3) 7 (11.7) 1 (50.0)
≥3 9 (13.8) 8 (13.3) 0
Note: Missing data is presented for only instances where it constitutes greater than 5%.
The p-values in bold format are statistically signiﬁcant. NA = not applicable.
Studies assessing drugs (147) or vaccines (118) exclusively do not add up to the total number of studies (268) because three studies that investigated both drugs
and vaccines are not presented in the table.
*Refers to journals that publish wide variety of medical topics (irrespective of specialty).
†Journals that do not ﬁt into any of the speciﬁed categories i.e. PLOS ONE.
‡For the age distributions, the proportions do not add up to 100% because some studies included multiple age categories.
§World Health Organization-Anatomic Therapeutic Chemical.
¶The proportions are based on only those studies that investigated speciﬁc compounds either exclusively or in combination with drug/vaccine class.
∥The proportions are based on only those studies that investigated drug/vaccine class either exclusively or in combination with speciﬁc compounds.
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Table 2. Methodology of 268 pharmacoepidemiological studies that evaluated the safety of drugs and vaccines in children (≤18 years)
Total (268)
Type of exposure investigated
Only drugs (147) Only vaccines (118)
Number(%) or median(Q1–Q3) Number(%) or median(Q1–Q3) Number(%) or median(Q1–Q3) p-Value
Design*
Cohort 174 (64.9) 114 (77.6) 60 (50.8) <0.01
Case control 73 (27.2) 31 (21.1) 39 (33.1) 0.03
Self-controlled case series 30 (11.2) 0 30 (25.4) NA
Case crossover 4 (1.5) 3 (2.0) 1 (0.8) 0.42
Others† 14 (5.2) 6 (4.1) 8 (6.8) 0.33
Mode of data collection‡
Retrospective 177 (66.0) 96 (65.3) 80 (67.8) 0.66
Prospective 69 (25.7) 41 (27.9) 26 (22.0) 0.27
Both 19 (7.1) 10 (6.8) 9 (7.6) 0.80
Unclear§ 3 (1.1) 0 3 (2.5) NA
Type of data 0.11
Primary 58 (21.6) 38 (25.9) 18 (15.3)
Secondary 183 (68.3) 95 (64.6) 87 (73.7)
Mixed 27 (10.1) 14 (9.5) 13 (11.0)
Source of (collection method for) exposure data¶
Primary care (prescription) data 27 (10.1) 14 (9.5) 12 (10.2) 0.85
Outpatient (pharmacy) dispensing data 19 (7.1) 7 (4.8) 12 (10.2) 0.09
Inpatient dispensing data 21 (7.8) 18 (12.2) 2 (1.7) <0.01
Paper medical chart 85 (31.7) 54 (36.7) 29 (24.6) 0.03
Claims data 55 (20.5) 25 (17.0) 30 (25.4) 0.09
Registry 35 (13.1) 16 (10.9) 19 (16.1) 0.21
Self-report questionnaire 12 (4.5) 7 (4.8) 5 (4.2) 0.82
Telephone call 13 (4.9) 5 (3.4) 8 (6.8) 0.20
Face to face interview 17 (6.3) 6 (4.1) 10 (8.5) 0.14
Others∥ 40 (14.9) 15 (10.2) 25 (21.2) 0.01
Unclear** 13 (4.9) 7 (4.8) 6 (5.1) 0.91
Source of (collection method for) outcome data††
Primary care data 29 (10.8) 14 (9.5) 15 (12.7) 0.41
Paper medical charts 122 (45.5) 66 (44.9) 53 (44.9) 1.00
Institution, administrative or electronic heath records 60 (22.4) 23 (15.6) 37 (31.4) <0.01
Claims data 71 (26.5) 32 (21.8) 38 (32.2) 0.06
Registry 38 (14.2) 21 (14.3) 17 (14.4) 0.98
Self-report questionnaire 25 (9.3) 13 (8.8) 12 (10.2) 0.70
Telephone call 13 (4.9) 8 (5.4) 5 (4.2) 0.65
Face to face interview 12 (4.5) 6 (4.1) 6 (5.1) 0.70
Others‡‡ 32 (11.9) 18 (12.2) 14 (11.9) 0.94
Unclear§§ 4 (1.5%) 3 (2.0) 1 (0.8) 0.42
Size of the study population per design
Fixed cohort
Exposed, number of participants 2050 (103–34 544) 283 (51–12 432) 44 001 (4009–278 624) <0.01
Unexposed, number of participants 1073 (74–27 417) 372 (58–8533) 24 175 (1215–227 288) 0.67
Missing data 18 (32.2) 6 (6.2) 12 (30.8)
Dynamic cohort [person-years(PY)]
Exposed PY 92 835 (11 931–731 043) 62 383 (3600–416 018) 123 287 (14 708–1 220 006) 0.56
Unexposed PY 362 142 (9235–1 315 038) 162 622 (5485–1 728 969) 535 375 (17 496–1 298 601) 0.90
Case–control
Cases 189 (68–467) 79 (30–532) 252 (133–452) 0.03
Number of controls per case 2.2 (1.1–4.2) 2.1 (1.0–4.4) 2.8 (2.0–4.1) 0.24
SCCS and Case Crossover, number of participants 402 (168–1380) NA 369 (173–1334) NA
Missing data 5 (14.7) 0 5 (16.1)
Control of confounding¶¶
Matching 98 (36.6) 43 (29.3) 53 (44.9) <0.01
Stratiﬁcation 103 (38.4) 36 (24.5) 66 (55.9) <0.01
Multivariate modeling adjustment 138 (51.5) 75 (51.0) 60 (50.8) 0.97
Note: Missing data is presented for only instances where it constitutes greater than 5%.
The p-values in bold format are statistically signiﬁcant. NA = not applicable.
Studies assessing drugs (147) or vaccines (118) exclusively, do not add up to the total number of studies (268) because three studies that investigated both
drugs and vaccines are not presented in the table.
*The proportions do not add up to 100% because some studies applied multiple designs.
†Includes study designs that are not listed, i.e. case-time-control.
‡The proportions do not add up to 100% because some studies applied multiple data collection modes.
§Implies that there was inadequate information to determine if data collection was done prospectively or retrospectively.
¶The proportions do not add up to 100% because some studies applied multiple sources (or collection modes for) exposure data.
∥Includes data sources (or collection methods) that are not speciﬁed e.g. maternal and child health handbook.
**Implies that there was inadequate information to determine the source of (or collection mode for) the exposure data.
††The proportions do not add up to 100% because some studies applied multiple sources (or collection modes for) outcome data.
‡‡Includes data sources (or collection methods) that are not speciﬁed, e.g. maternal and child health handbook.
§§Implies that there was inadequate information to determine the source of (or collection mode for) the outcome data.
¶¶The proportions do not add up to 100% because some studies applied methods to control confounding.
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assessed two classes and 8 (13.3%) investigated three
or more. Fourteen studies (23.3%) evaluated ‘antibac-
terials for systemic use’, 10 (16.7%) assessed
psychoanaleptics and 7 (11.7%) assessed
psycholeptics. Considering 14 drug safety studies that
included preterm newborns, ‘antibacterials for sys-
temic use’ were evaluated in 3 (21.4%) and ‘cortico-
steroids for systemic use’ in 2 (14.3%). For details of
studied drug by age, see electronic Supporting
Information.
Across the 150 studies that assessed drugs whether
exclusively or with vaccines, a total of 291 unique ex-
posures representing 39 unique classes (WHO-ATC
second level) were investigated. Psychoanaleptics (53
[18.2%]) were the commonest, followed by ‘antibacte-
rials for systemic use’ (40 [13.7%]) and psycholeptics
(38 [13.1%]). For further details, see Table 3.
Considering drug evaluations exclusively, only
three studies (2.0%) assessed the effect of rarely used
drugs (i.e. ciproﬂoxacin) and only 30 (20.0%) assessed
dose-effects.
Altogether, 588 outcomes were evaluated with a
median of 1(1–2) outcome per study; 36 studies
(13.4%) did not state the outcome deﬁnition. Most
events (68 [39.5%]) were acute, and deﬁned as
symptoms, signs or ill-deﬁned conditions (i.e. diar-
rhea) (Figure 3). Rare outcomes (i.e. Stevens–Johnson
syndrome) were evaluated in only 17 studies (6.3%).
Expert validation of the outcomes was frequent (172
[64.2%]) but only in 46 of those (26.7%) the experts
were blinded to exposure.
Out of 174 cohort studies, the follow-up time was in-
adequate to observe the investigated outcomes in 76
(43.7%).
Only 27 studies (10.1%) reported sample size or
power calculations. Cohort studies were the largest
Table 3. Twenty most frequently investigated drug classes across the 150
studies that investigated drugs (whether exclusively or with vaccines)
Drug class (WHO-ATC second level)* Code N (%)†
Psychoanaleptics N06 53 (18.2)
Antibacterials for systemic use J01 40 (13.7)
Psycholeptics N05 38 (13.1)
Antineoplastic agents L01 30 (10.3)
Anti-inﬂammatory and
anti-rheumatic products
M01 18 (6.2)
Anti-epileptics N03 12 (4.1)
Corticosteroids for systemic use H02 11 (3.8)
Analgesics N02 10 (3.4)
Contrast media V08 8 (2.7)
Immunosuppresants L04 7 (2.4)
Anesthetics N01 6 (2.1)
Antihistamines for systemic use R06 6 (2.1)
Antihemorrhagics B02 5 (1.7)
Pituitary and hypothalamic
hormones and analogues
H01 5 (1.7)
Antivirals for systemic use J05 5 (1.7)
Drugs for obstructive airway
diseases
R03 4 (1.4)
Cardiac therapy C01 3 (1.0)
Cough and cold preparations R05 3 (1.0)
Drugs for functional
gastrointestinal disorders
A03 2 (0.7)
Agents acting on the renin-
angiotensin system
C09 2 (0.7)
*World Health Organization-Anatomic Therapeutic Chemical classiﬁcation.
†Proportion is based on the total number (291) of unique drug exposures
that were investigated.
Figure 3. Distribution of papers according to the main divisions of the International Classiﬁcation of diseases (ninth edition), and type of exposure. Note:
‘Certain conditions originating in the perinatal period’ includes ‘Other conditions originating in the perinatal period’ (764–779) which does not include ma-
ternal causes, i.e. Necrotizing enterocolitis (777.5); ‘Injury and poisoning’ includes ‘unspeciﬁed adverse effect of drug medicinal and biological substance not
elsewhere classiﬁed’ (995.2)
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unlike SCCS and case crossover studies which in-
cluded few participants. Most studies (229 [85.4%])
adjusted for confounding either by stratiﬁcation
(mainly vaccine safety studies), matching or by multi-
variate modeling (mainly drug safety studies).
Only 133 studies (49.6%) speciﬁed a primary objec-
tive and 129 studies (48.1%) reported at least one sta-
tistically signiﬁcant result. This proportion increased
to 59.0% when only 183 child-speciﬁc studies were
considered. Most studies with signiﬁcant statistical re-
sults (97 [75.2%]) were published after 2002. Among
the 75 child-speciﬁc studies that did not present any
statistically signiﬁcant result, 41 (54.7%) did not dis-
cuss lack of power.
DISCUSSION
We have conducted a systematic review to assess the
characteristics of pediatric pharmacoepidemiological
safety studies that were published over 34years, while
aiming to identify areas for improvement of these
much needed studies. The review also highlights dif-
ferences in drug versus vaccine pediatric studies.
Some previous reviews have summarized evidence
regarding speciﬁc drug or vaccine safety issues that af-
fect children12–15 while others have focused on
speciﬁc methodological aspects of pediatric
pharmacoepidemiology16–17 but to the best of our
knowledge no review has attempted to provide a gen-
eral overview of these studies.
Our main ﬁndings are: the absolute number of pedi-
atric pharmacoepidemiological safety studies is low; in
2012 only 33 studies concerned pediatrics compared
to a total of 3197 published studies (data not presented
but utilized in constructing Figure 2). Such studies are
almost exclusively conducted in developed countries
and receive very little private funding. Evaluated
exposures concern few pharmaceuticals while
investigating mainly intermediate clinical outcomes
(signs/symptoms). As areas of improvement we rec-
ommend better global spread, interaction between
pharmacoepidemiologists evaluating drugs and vac-
cines to apply designs more broadly, more focus and
funding of such studies, and collaboration between in-
vestigators so that larger size studies can be conducted
that may have enough power to study the rarer and po-
tentially more serious safety issues.
Although paper medical charts may be regarded as
the gold standard source of patient information elec-
tronic health records and claims data comprise vast
amounts of routine care information that can be readily
utilized for pharmacoepidemiological safety studies,
as demonstrated by several authors.18–21 More
extensive use of such data may be needed to overcome
the problem of inadequate follow-up for many cohort
studies as demonstrated in this review, especially if
this is related to the high costs that is associated with
long follow-up time in some prospective studies utiliz-
ing primary data collection. Generally, the potential of
secondary data has been recognized by FDA in Senti-
nel,22 by Health Canada in their CNODES project23
and in Europe by the GRIP consortium and other pro-
jects.24 We should now focus the potential of these
powerful resources on pediatric studies speciﬁcally in
order to quickly ﬁll the existing gap in knowledge of
drug use.
The number of pediatric safety studies started in-
creasing steadily after 2002, following the introduction
of the ‘Best Pharmaceuticals for children Act’
(BPCA).3 Under the BPCA, the US National Institutes
of Health sponsored several pharmacoepidemiological
studies in children.25 The pediatric regulation was in-
troduced in the European Union in 2007, perhaps
explaining the even steeper increase in the number of
pediatric studies that is observed after 2007 (Figure
2). The predominance of US and EU studies may be
explained partially by these legislations but also by
the number of epidemiologists and data resources.
Whatever the explanation may be, this review points
to a large public health need for more human capacity
building and studies in many children that live in other
parts of the world, particularly lower and middle
income countries. From a publication and academic
perspective it should be noted that the studies were
published mostly in more general journals and the im-
pact factors were well above the median in the phar-
macology ﬁeld.
Where should funding for such studies come from?
Generally, studies relying on secondary data are af-
fordable. In this review we observed that few studies
were privately funded. We recommend that the politi-
cians who passed the BPCA and other legislations to
stimulate generation of efﬁcacy data in children see
the potential of pharmacoepidemiology rather than
clinical trials to generate safety data and oblige long-
term postmarketing studies in children for newly
marketed drugs speciﬁcally. Studies on off-patent
drugs that are frequently used in children should be in-
vestigated through public funding in both developing
and developed countries.
Almost half of the evaluated drugs belong to only
three classes (Table 3): anti-infectives,
psychoanaleptics and psycholeptics. Although anti-
infectives are often prescribed in pediatrics across all
age groups, psychoanaleptics and psycholeptics repre-
sent a minority of drug exposure in children.26
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However, these drugs have been surrounded by spe-
ciﬁc safety issues.27–28 Speciﬁcally, psychoanaleptics
(i.e. atomoxetine and methylphenidate) were com-
monly mentioned in pediatric case reports submitted
to FAERS between 2004 and 2011,29 probably
reﬂecting its increased use and high risk of toxicity,
notably cardiovascular toxicity, as demonstrated by
several authors in our review.27–28,30–32
Very few studies evaluated rare drug exposures pos-
sibly because such studies would not have been
adequately powered to detect an association. Speciﬁ-
cally, in preterm newborns, the investigated drugs
(i.e. sildenaﬁl and morphine) are possibly associated
with serious safety issues;33–35 however, these studies
could not conﬁrm safety associations possibly because
of their limited sample size. Inadequate sample size
may account for the lack of at least one statistically
signiﬁcant result in 41% of the child-speciﬁc studies,
even if majority of these studies did not discuss lack
of power. Size issues may be addressed by
implementing case-only (i.e. SCCS) designs.36 In our
review, few studies applied case-only analysis essen-
tially to evaluate vaccine safety. However, case-only
designs present strengths that are suited for the drug
utilization patterns and characteristics of outcomes in
children.37–38 Further, multi-site data pooling may be
necessary to acquire adequate power to study rare
events in children.39–40 International collaboration on
a global scale may be required; this is the main aim
of the Global Research in Pediatrics (GRIP) project.
The strength of this review is the systematic assess-
ment of pharmacoepidemiological safety studies in
children, with broad inclusion criteria. Regarding lim-
itations, we applied minimum follow-up periods (to
cohort studies) according to the type of investigated
outcome; this may not have been accurate for some
speciﬁc outcomes. Yet, standardization was necessary
because the outcomes were numerous and highly het-
erogeneous. Also, the ﬁndings we have presented are
based on published data reported by authors of the
studies; therefore, if such reporting was incomplete
and/or inaccurate, this may have impacted our ﬁnd-
ings. For example, several irrelevant drug exposures
were assessed in neonates (electronic Supporting In-
formation), like anti-obesity preparations or antineo-
plastic drugs merely because authors stated that
included pediatric population started at 0 years of
age. Such imprecisions inevitably lead to erroneous
conclusions. Also, we used country of corresponding
author as a proxy for the study setting; by doing this,
study setting for multi-country database studies may
not have been accurately captured. Further, we used
the journal impact factor as a proxy for the quality of
the studies that we reviewed; the limitations of this
measure have been described in the literature.
Based on the reviewed literature, we conclude that
there is a need to build global collaborative capacity
and funding opportunities for pediatric
pharmacoepidemiology because this is one of the most
powerful ways to provide evidence of drug safety in
children.
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Key points
• The number of pharmacoepidemiological safety
studies is steadily increasing in pediatrics
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the investigated population, studied drugs and
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• Pharmacoepidemiological safety studies in chil-
dren can be improved in several ways including
global collaboration.
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